Cargill wins EU novel foods approval for omega-6 form ARA

By Shane Starling

- Last updated on GMT

Related tags: Infant formula, European union, Docosahexaenoic acid

Cargill wins EU novel foods approval for omega-6 form ARA
Cargill is celebrating the European Union approval of a Mortierella alpine, algae fermented arachidonic acid (ARA)-rich oil, to be used in infant formula and formula for older children.

ARA is commonly found in such products in conjunction with omega-3 form, docosahexaenoic (DHA), and is found naturally in breast milk. Cargill’s version can now enter the infant formula supply dominated by DSM-Martek under the EU infant formula directive.

"Cargill is pleased that we now have the opportunity to help our European customers develop premium infant formulas using Cargill's ARA,"​ said David Henstrom, vice president of Cargill Health & Nutrition.

"This approval is the culmination of a series of regulatory efforts that, coupled with our increased capacity, now enables us to fulfill the needs of our infant formula customers in Europe."

The ingredient won generally recognised as safe (GRAS) approval from the Food and Drug Administration's (FDA) at the beginning of 2011.

The scientific literature points to brain and vision benefits for infants for ARA, although the European Food Safety Authority (EFSA) refused a claim for ARA and DHA that sought to state that, DHA and ARA, “contribute to the optimal brain development of infants and young children”.

Most infant formulas contain ARA to DHA ratios of about 2:1.

Cargill opened a Chinese facility in 2010 to boost its ARA production.

Claims

The rejected DHA-ARA claim in question was submitted by Merck Selbstmedikation GmbH in 2009 and followed global algae-sourced DHA leader, Martek Biosciences, which had a similar DHA-ARA dossier turned down in the first series of opinions in the second half of 2008.

The German firm recommended mothers consume 200mg of DHA per day during and after pregnancy to confer eye health and brain health benefits in the foetus and infant. But EFSA’s Panel on Dietetic Products, Nutrition and Allergies (NDA) said, “There is insufficient evidence to establish a cause and effect relationship.”

Related news

Show more

Related products

show more

TINOFOLIN®: ADAPTOGEN FOR LEARNING & MEMORY

TINOFOLIN®: ADAPTOGEN FOR LEARNING & MEMORY

SABINSA | 11-May-2020 | Data Sheet

Tinospora cordifolia, used in Ayurveda for anti-aging, longevity, promoting intelligence, improving memory, and imparting immunomodulation properties,...

Pycnogenol® Provides Benefits for Men Managing ED

Pycnogenol® Provides Benefits for Men Managing ED

Horphag Research | 17-Feb-2020 | Clinical Study

Newly published research shows daily supplementation with Pycnogenol® can strengthen erectile function and address common conditions related to type 2...

HRB are ideal probiotics for human health

HRB are ideal probiotics for human health

Morinaga Milk Industry Co., Ltd. | 13-Jan-2020 | Technical / White Paper

Evidence is accumulated that the physiological benefits of probiotics bifidobacteria are not only strain-specific but also dependent on their residential...

Related suppliers

Follow us

Featured Events

View more

Products

View more

Webinars